Site search

Clear filter
2898 results for '' found
SODium BICarbonate for metabolic acidosis in the Intensive Care Unit: A pilot, multicentre,randomized, double-blindclinical trial. (ACTRN12620001361998)
SODium BICarbonate for metabolic acidosis in the Intensive Care Unit: A pilot, multicentre,randomized, double-blindclinical trial. (ACTRN12620001361998)
/
SODa-BIC: Sodium Bicarbonate For Metabolic Acidosis in the Intensive Care Unit, A Multicentre, Randomised, Double-Blind Clinical Trial (NCT05697770)
SODa-BIC: Sodium Bicarbonate For Metabolic Acidosis in the Intensive Care Unit, A Multicentre, Randomised, Double-Blind Clinical Trial (NCT05697770)
/
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (ACTRN12621001444875p)
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (ACTRN12621001444875p)
/
A PHASE 1, OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SNV1521 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS (NCT06220864)
A PHASE 1, OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SNV1521 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS (NCT06220864)
/
Stereotactic ablative body radiation therapy with Nodal Irradiation for ProstatE canceR (ACTRN12625000259448)
Stereotactic ablative body radiation therapy with Nodal Irradiation for ProstatE canceR (ACTRN12625000259448)
/
Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with
/
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or
/
Sugammadex, neostigmine and postoperative pulmonary complications (the SNaPP Study) (ACTRN12623000394640)
/
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
/
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
/
18 19 20 21 22